Lysine

Lysine

SCHEMBL668975

NCCCCC(N)C(=O)O.NCCCCC(N)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 2/20 1.00
▸ ARG2 P78540 4/20 0.59
▸ ARG1 P05089 3/20 0.59
▸ RNPEP Q9H4A4 1/20 0.58
▸ CYP1A2 P05177 3/20 0.52
▸ GRM8 O00222 1/20 0.52
▸ GRM6 O15303 1/20 0.52
▸ GRIN2D O15399 1/20 0.52
▸ GRIN3B O60391 1/20 0.52
▸ GRIK1 P39086 1/20 0.52
▸ GRM5 P41594 1/20 0.52
▸ GRIA1 P42261 1/20 0.52
▸ GRIA2 P42262 1/20 0.52
▸ GRIA3 P42263 1/20 0.52
▸ SLC1A3 P43003 1/20 0.52
▸ SLC1A2 P43004 1/20 0.52
▸ SLC1A1 P43005 1/20 0.52
▸ GRIA4 P48058 1/20 0.52
▸ GRIN1 Q05586 1/20 0.52
▸ GRIN2A Q12879 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysine SCHEMBL12867528 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL1000151 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL20362357 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL7343 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL3359527 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL9439278 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL2802757 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL15303774 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL456381 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL1645 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020135658-A1 POLYPEPTIDE HAVING PHOSPHOLIPASE C ACTIVITY AND USE THEREOF 丰益(上海)生物技术研发中心有限公司 2020-07-02 — — WO claimed
CN-110250349-A A kind of big swine feed of reinforcing reducing the thickness of backfat 正大康地阳江饲料有限公司 2019-09-20 — — CN claimed
CN-110250350-A A kind of low small swine feed of brotein equilibrium amino acid 正大康地阳江饲料有限公司 2019-09-20 — — CN claimed
CN-105316270-B Engineering bacterium for catalytically producing 1, 5-pentanediamine and application thereof 宁夏伊品生物科技股份有限公司 2019-01-29 — — CN claimed
EP-3309167-A1 SMALL-MOLECULE POLYPEPTIDE ZY4 AND APPLICATION THEREOF Sichuan Hetai Synlight Biotech Ltd. (CN) 2018-04-18 — — EP claimed
CN-106904635-A It is a kind of to be aided in by amino acid under dense gel rubber system and be segmented method of the crystallization coordinate system for nano molecular sieve 吉林大学 2017-06-30 — — CN claimed
US-8501679-B2 Cyclic, cystein-free protein APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) 2013-08-06 — — US claimed
EP-2217619-B1 CYCLIC, CYSTEIN-FREE PROTEIN APEPTICO FORSCHUNG & ENTWICKLUNG GMBH (AT) 2012-11-07 — — EP claimed
US-20110105414-A1 CYCLIC, CYSTEIN-FREE PROTEIN APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) 2011-05-05 — — US claimed
EP-2217619-A1 CYCLIC, CYSTEIN-FREE PROTEIN Apeptico Forschung Und Entwicklung Gmbh (AT) 2010-08-18 — — EP claimed
EP-1740698-B1 RECOMBINANTLY MODIFIED PLASMIN TALECRIS BIOTHERAPEUTICS INC (US) 2010-08-04 — — EP claimed
WO-2009073909-A1 CYCLIC, CYSTEIN-FREE PROTEIN APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) 2009-06-18 — — WO claimed
CN-1325063-C L-amino acid water-soluble pearl powder and its preparing method SONG TINGSHENG (CN) 2007-07-11 — — CN claimed
CN-1308690-C Novel method and kit for sequencing polypeptides PROCTER & GAMBLE (US) 2007-04-04 — — CN claimed
CN-1709282-A L-amino acid water-soluble pearl powder and its preparing method SONG TINGSHENG (CN) 2005-12-21 — — CN claimed
CN-1551984-A Novel method and kit for sequencing polypeptides — 2004-12-01 — — CN claimed
US-11826399-B2 Chlorotoxin agents and uses thereof EISAI INC. (US) 2023-11-28 — — US disclosed
CN-116694539-B Lactobacillus plantarum J26 as direct vat set starter, and preparation method and application thereof 东北农业大学 2023-11-17 — — CN disclosed
US-5227166-A Core of active material, stable coating of lecithin, inorganic salt, and hardened oil or wax AJINOMOTO CO., INC. (JP) 1993-07-13 — — US disclosed
WO-1992008341-A1 NOVEL PRODUCTION METHOD FOR CORN WITH ENHANCED QUALITY GRAIN TRAITS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1992-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11826399-B2 Chlorotoxin agents and uses thereof NRP1, LCP1, CLSPN GSR 3695/4885ARG2 1803/4885ARG1 904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback